Article Abstract

Preclinical randomized controlled multicenter trials in translational stroke research

Authors: Sergio Amaro, Laura Llull


Natalizumab is a humanized monoclonal antibody against alpha-4 integrin (CD49d) that reduces the incursion of circulating leukocytes into the central nervous system across the endothelium (1).


  • There are currently no refbacks.

Article Options

Download Citation